Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
LifeStance Health Group (LFST) has drawn investor attention after a mixed stretch, with a small gain over the past week, a decline over the past month, and a stronger move over the past 3 months.
Over 1 year, the stock shows a negative total return, while the 3 year total return figure is positive, giving investors a contrasting picture of shorter versus longer term performance.
See our latest analysis for LifeStance Health Group.
At a share price of $7.03, LifeStance Health Group shows mixed momentum, with a 12.48% 90 day share price return alongside a 1 year total shareholder return of an 11.79% loss. This hints at improving sentiment after a tougher year.
If this kind of rebound in sentiment has your attention, it could be a good moment to check out our screener of healthcare focused AI opportunities through 25 healthcare AI stocks as a way to broaden your watchlist beyond LFST.
So with LifeStance showing a recent 90 day rebound, reporting revenue and net income growth but still posting a net loss and trading below the average analyst price target, is this a genuine entry point or is the market already pricing in future growth?
At $7.03, the most followed narrative tags LifeStance Health Group with a higher fair value, using a detailed set of growth and profitability assumptions to get there.
The continued and accelerating demand for mental health services in the U.S., driven by increasing public awareness and access to insurance coverage, is expected to expand LifeStance’s addressable market and support sustained double-digit revenue growth in the coming years.
Want to see what is baked into that higher fair value? The narrative leans heavily on future revenue growth, rising margins and a richer earnings multiple. Curious how those pieces fit together to support the current target and fair value gap?
Result: Fair Value of $8.43 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, this hinges on LifeStance managing insurer reimbursement pressure and clinician retention; any setback here could quickly challenge the current growth-focused narrative.
